Market News AIOpen the app

Larimar Therapeutics reported a $31.1 million loss last quarter and finished its drug application for Friedreich's ataxia.

ResultsRead the original at SEC EDGAR
Good for LRMR

Larimar completed its application, and the FDA said its data could support review, moving its treatment closer to a possible launch. Its loss narrowed, but cash is projected to last only into late Q2 2027, before its Q3 launch target, and approval is not assured.

LRMR · Larimar Therapeutics, Inc.

AI read · Good for LRMR

The AI's read

The FDA said the existing data could support review and may consider skin frataxin levels as a measure. This makes a review path clearer, but approval is not assured. Larimar's quarterly loss narrowed to $31.1 million from $47.7 million, mostly because drug-making costs fell. Its $128.7 million in cash is projected to last into late Q2 2027, before the targeted Q3 2027 launch, if approved.

Get alerts for LRMR

Follow Larimar Therapeutics, Inc. (LRMR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LRMR
Free on the App Store and Google Play, or on the web.